FDA approves new labelling for Seroquel in bioplar mania
Alderley Park, UK — 23 July, 2004 -- ......AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) has approved additional efficacy labelling information based on 12-week data for SEROQUEL (quetiapine), a psychotropic medication indicated for the treatment of acute manic episodes associated with bipolar I disorder. The data 1, part of the large scale effort to examine S...New data shows Seroquel achieves remission in bipolar mania
Alderley Park, England — May 7, 2004 — AstraZeneca announced important new data today that show patients with bipolar disorder who were treated with SEROQUEL (quetiapine) were significantly more likely to achieve full remission of their mania symptoms compared to patients who received placebo. The data were presented at the 157th American Psychiatric Association (APA) congress....... A...Seroquel: New data show efficacy and tolerablity in bipolar depression
Alderley Park, England — May 6, 2004 — AstraZeneca announced important new data today presented at the 157th American Psychiatric Association (APA) congress from the first large-scale clinical trial to examine SEROQUEL (quetiapine) as a treatment for depressive episodes in patients with bipolar I and II disorders. The results show that SEROQUEL is an effective and well-tolerated agent f...New data suggests Seroquel improves quality of life in first episode schizophrenia
Davos, Switzerland 13 February 2004 New data presented at the sixth scientific meeting of the European First Episode Schizophrenia Network, show that patients suffering their first episode of psychosis benefit from significant symptom improvement and enhancement of overall quality of life, when treated with the atypical antipsychotic, Seroquel (quetiapine).... ...Interim one year follow-up resu...Astrazeneca receives European approval for Seroquel; in bipolar mania
Sodertalje, Sweden, 13 October 2003 - AstraZeneca announced today that it has successfully completed the Mutual Recognition Procedure (MRP) involving 14 European countries to extend the use of SEROQUEL (quetiapine) to the treatment of mania associated with bipolar disorder (manic-depressive illness). SEROQUEL is also under review for bipolar mania in the United States with the FDA and in the UK...